This genetic abnormality results in the production of the BCR-ABL fusion protein, which leads to persistent activation of the tyrosine kinase activity of BCR-ABL and is the pathophysiological cause of CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.